Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
CD27/TNFRSF7 Mouse anti-Human, Clone: 203.6, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NBP2479140.2MG
Description
CD27/TNFRSF7 Monoclonal antibody specifically detects Antigen in Human samples. It is validated for Flow Cytometry, Immunofluorescence.Specifications
CD27/TNFRSF7 | |
Monoclonal | |
1.0 mg/mL | |
Flow Cytometry : 0.5 - 1 ug/million cells in 0.1 ml, Immunofluorescence : 0.5 - 1.0 ug/ml, CyTOF-ready | |
CD27 antigen, CD27 molecule, MGC20393, S152CD27L receptor, T cell activation antigen CD27, T cell activation antigen S152, T14, TNFRSF7T-cell activation antigen CD27, Tp55, Tumor necrosis factor receptor superfamily member 7, tumor necrosis factor receptor superfamily, member 7 | |
Mouse | |
120 kDa | |
0.2 mg | |
Apoptosis, B Cell Development and Differentiation Markers, Cancer, Immunology, Innate Immunity | |
939 | |
Human | |
Purified |
Flow Cytometry, Immunofluorescence, CyTOF | |
203.6 | |
Unconjugated | |
PBS with No Preservative | |
CD27 | |
Sezary cells | |
Protein A or G purified | |
RUO | |
Primary | |
Recognizes a protein of a disulfide-linked 120kDa dimer, identified as CD27 (Workshop VI; Code 6T-028). CD27 is expressed on the majority of peripheral T cells, medullary thymocytes, memory-type B cells, and natural killer cells. It is a transmembrane phosphoglycoprotein that belongs to the tumor necrosis factor receptor (TNFR) superfamily. CD27 binds to its ligand CD70, a member of the TNF family, and induces T-cell co-stimulation and B-cell activation. It also interacts with TRAFs and is involved in activation of NFB and SAPK/JNK and induces apoptosis. | |
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. | |
IgG3 κ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction